From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...

FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...

The report is the latest indictment of America’s broken healthcare system.

The Federal Trade Commission accuses CVS, Cigna and UnitedHealth of artificially inflating prices on specialty generic drugs ...

WASHINGTON >> The nation’s three largest pharmacy benefit managers have significantly marked up the prices of certain ...

The U.S. Federal Trade Commission (FTC) has slammed pharmacy benefit managers (PBMs) owned by UnitedHealth ($UNH), CVS Health ...

UnitedHealth Group (NYSE:UNH) reported the fourth-quarter 2024 earnings and reaffirmed 2025 guidance. The company reported ...

The FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty ...

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

The Big 3 companies acting as intermediaries between drugmakers and insurance providers made billions by needlessly jacking ...

The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...